Eikon Therapeutics Announces Availability of Seven Abstracts for Presentation at the European Society for Medical Oncology Congress
Eikon Therapeutics announced availability of seven abstracts covering its four clinical candidates for presentation at the 2026 ESMO Congress in Madrid beginning October 23. The presentations include updated TeLuRide-005 Phase 2 data for EIK1001 in stage 4 NSCLC, Phase 1/2 data for the PARP1 inhibitors EIK1003 and EIK1004, and preliminary safety/PK data for the WRN helicase inhibitor EIK1005.
Key figures
- Drug Name
- EIK1001, EIK1003, EIK1004, EIK1005
- Phase Of Trial
- Phase 1/2 and Phase 2
- Abstract count
- 7
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.